Electromed Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Electromed wird ein Gewinn- und Umsatzwachstum von 19.7% bzw. 11.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 15.8% pro Jahr wachsen soll.

Wichtige Informationen

19.7%

Wachstumsrate der Gewinne

15.8%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.6%
Wachstumsrate der Einnahmen	11.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	08 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

What Percentage Of Electromed, Inc. (NYSEMKT:ELMD) Shares Do Insiders Own?

Mar 07

Is Electromed, Inc.'s (NYSEMKT:ELMD) Latest Stock Performance A Reflection Of Its Financial Health?

Feb 17

Electromed, Inc.'s (NYSEMKT:ELMD) Intrinsic Value Is Potentially 90% Above Its Share Price

Dec 16

Announcing: Electromed (NYSEMKT:ELMD) Stock Soared An Exciting 405% In The Last Five Years

Dec 04

How Is Electromed's (NYSEMKT:ELMD) CEO Paid Relative To Peers?

Nov 22

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:ELMD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2025	61	6	N/A	N/A	1
6/30/2024	55	5	N/A	N/A	1
3/31/2024	53	4	5	6	N/A
12/31/2023	52	4	4	5	N/A
9/30/2023	50	3	1	3	N/A
6/30/2023	48	3	0	1	N/A
3/31/2023	46	3	-2	0	N/A
12/31/2022	44	2	-3	-1	N/A
9/30/2022	42	2	-3	-2	N/A
6/30/2022	42	2	-2	-1	N/A
3/31/2022	40	2	0	1	N/A
12/31/2021	39	2	1	1	N/A
9/30/2021	38	2	1	2	N/A
6/30/2021	36	2	3	3	N/A
3/31/2021	33	3	3	4	N/A
12/31/2020	33	4	3	4	N/A
9/30/2020	32	4	4	4	N/A
6/30/2020	32	4	3	4	N/A
3/31/2020	34	4	2	4	N/A
12/31/2019	33	4	2	4	N/A
9/30/2019	32	3	1	3	N/A
6/30/2019	31	2	1	3	N/A
3/31/2019	31	2	1	2	N/A
12/31/2018	30	2	1	2	N/A
9/30/2018	29	2	2	2	N/A
6/30/2018	28	2	2	2	N/A
3/31/2018	28	2	2	2	N/A
12/31/2017	27	2	N/A	3	N/A
9/30/2017	27	2	N/A	3	N/A
6/30/2017	26	2	N/A	1	N/A
3/31/2017	24	2	N/A	1	N/A
12/31/2016	24	1	N/A	1	N/A
9/30/2016	23	2	N/A	1	N/A
6/30/2016	23	2	N/A	2	N/A
3/31/2016	22	2	N/A	3	N/A
12/31/2015	21	2	N/A	3	N/A
9/30/2015	20	1	N/A	2	N/A
6/30/2015	19	1	N/A	3	N/A
3/31/2015	19	1	N/A	3	N/A
12/31/2014	18	0	N/A	2	N/A
9/30/2014	17	-1	N/A	2	N/A
6/30/2014	15	-1	N/A	2	N/A
3/31/2014	15	-2	N/A	2	N/A
12/31/2013	14	-1	N/A	2	N/A
9/30/2013	14	-2	N/A	3	N/A
6/30/2013	15	-1	N/A	2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ELMDDas prognostizierte Gewinnwachstum (19.7% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: ELMDDie Erträge des Unternehmens (19.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: ELMDDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ELMDDie Einnahmen des Unternehmens (11.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ELMDDie Einnahmen des Unternehmens (11.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ELMD in 3 Jahren voraussichtlich hoch sein wird

Electromed Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 25%, revenue upgraded

Price target increased to US$16.75

Consensus forecasts updated

Electromed, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter Ended June 30, 2021

Consensus forecasts updated

Price target increased to US$18.00

Recent updates

Investor sentiment deteriorates as stock falls 17%

Third quarter 2024 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Electromed, Inc. to Report Q3, 2024 Results on May 07, 2024

Investor sentiment improves as stock rises 16%

President recently bought US$137k worth of stock

Investor sentiment improves as stock rises 48%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. to Report Q2, 2024 Results on Feb 13, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Electromed, Inc. Announces Launch of SmartVest Clearway Airway Clearance System

Electromed, Inc. to Report Q1, 2024 Results on Nov 07, 2023

Electromed, Inc., Annual General Meeting, Nov 10, 2023

Consensus EPS estimates fall by 25%, revenue upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Electromed, Inc. to Report Q4, 2023 Results on Aug 22, 2023

Electromed, Inc. Announces Appointment of Jim Cunniff as Its New President and Board of Director, Effective July 1, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

CEO, President & Director exercised options and sold US$245k worth of stock

Investor sentiment improves as stock rises 15%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. Announces Retirement of Kathleen Skarvan as Chief Executive Officer, Effective on or Around July 1, 2023

Electromed, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Electromed, Inc. Announces U.S. Food and Drug Administration 510(K) Clearance of Fifth Generation Hfcwo Airway Clearance Generator

Price target increased to US$16.75

First quarter 2023 earnings: EPS misses analyst expectations

Electromed, Inc. to Report Q1, 2023 Results on Nov 08, 2022

Electromed, Inc. Appoints Brad Nagel as Chief Financial Officer, Effective November 14, 2022

Electromed, Inc., Annual General Meeting, Nov 11, 2022

CEO, President & Director exercised options and sold US$59k worth of stock

Investor sentiment improved over the past week

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Electromed, Inc. to Report Q4, 2022 Results on Aug 23, 2022

High number of new directors

Electromed, Inc. Announces Election of Andrew Summers as Additional Independent Director

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. Announces Executive Changes

Electromed, Inc. to Report Q3, 2022 Results on May 10, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

First quarter 2022 earnings released: EPS US$0.051 (vs US$0.063 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$0.28 (vs US$0.49 in FY 2020)

Electromed, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter Ended June 30, 2021

Summers Value Fund Engages in Discussion with Electromed Shareholders

Electromed, Inc.(NYSEAM:ELMD) dropped from Russell 3000 Growth Index

Electromed, Inc. (NYSEAM:ELMD) announces an Equity Buyback for $3 million worth of its shares.

Consensus forecasts updated

Third quarter 2021 earnings released: EPS US$0.026 (vs US$0.078 in 3Q 2020)

Price target increased to US$18.00

What Percentage Of Electromed, Inc. (NYSEMKT:ELMD) Shares Do Insiders Own?

Is Electromed, Inc.'s (NYSEMKT:ELMD) Latest Stock Performance A Reflection Of Its Financial Health?

Analysts increase EPS estimates to US$0.34

Revenue and earnings beat expectations

Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.14 in 2Q 2020)

New 90-day high: US$10.76

Should You Be Impressed By Electromed's (NYSEMKT:ELMD) Returns on Capital?

Electromed, Inc. to Report Q2, 2021 Results on Feb 09, 2021

Did Electromed, Inc. (NYSEMKT:ELMD) Insiders Sell Shares?

Electromed (NYSEMKT:ELMD) Is Growing Earnings But Are They A Good Guide?

New 90-day high: US$10.40

Here's Why I Think Electromed (NYSEMKT:ELMD) Might Deserve Your Attention Today

Electromed, Inc.'s (NYSEMKT:ELMD) Intrinsic Value Is Potentially 90% Above Its Share Price

Announcing: Electromed (NYSEMKT:ELMD) Stock Soared An Exciting 405% In The Last Five Years

How Is Electromed's (NYSEMKT:ELMD) CEO Paid Relative To Peers?

Electromed, Inc. Names Andrea M. Walsh to Serve as an Additional Director

First quarter 2021 earnings released: EPS US$0.063

Revenue and earnings beat expectations

New 90-day low: US$8.60